Novira: Capsid counterattack

Novira developing therapeutics against viral capsids for HBV, HIV

Developing compounds against viral capsids is an attractive therapeutic strategy in theory, but has yet to work in practice because of the difficulty of inhibiting protein-protein interactions. Novira Therapeutics Inc. believes it has the right medicinal chemistry capabilities to develop small molecules that prevent capsid formation in HBV and HIV.

The capsid is a protein shell that forms around a virus to protect it during passage from one cell to another. "They do not have obvious binding sites, so there was

Read the full 805 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE